Research programme: oncobiotic therapeutics - Evelo BiosciencesAlternative Names: Immuno-microbiome Cancer therapies - Evelo Biosciences; Microbiome-based immuno-oncology therapeutics - Evelo Biosciences; Onco-microbials - Evelo Biosciences
Latest Information Update: 05 Aug 2016
At a glance
- Originator University of Chicago
- Developer Evelo Biosciences
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer